This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
earnings-estimates-revisions: Archive
How Much Upside is Left in Roku (ROKU)? Wall Street Analysts Think 27.39%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.4% in Roku (ROKU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ROKUNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
MRKNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Bulls Look Optimistic About Broadwind Energy (BWEN): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Broadwind Energy (BWEN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
BWENPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts Think MINISO Group Holding Limited (MNSO) Is a Good Investment: Is It?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), MINISO Group Holding Limited (MNSO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
MNSONegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Agnico (AEM) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Agnico (AEM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
AEMPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Should You Invest in GE (GE) Based on Bullish Wall Street Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in GE (GE). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
GEPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Bulls Look Optimistic About Palantir Technologies (PLTR): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Palantir Technologies (PLTR). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
PLTRPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in Workday (WDAY) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Workday (WDAY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
WDAYPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts See ARKO (ARKO) as a Buy: Should You Invest?
by Zacks Equity Research
The average brokerage recommendation (ABR) for ARKO (ARKO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ARKONegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
XERSNegative Net Change
earnings earnings-estimates-revisions earnings-surprise